Investigating the reasons behind the stall in the decline of cardiovascular disease deaths in the U.S. and the new scientific innovations emerging from Harvard labs that aim to improve treatment and drive death rates down.

With funding and business development support from the Blavatnik Biomedical Accelerator, a research team’s lab discovery propelled to startup success.

Kinvard Bio is creating a new class of antibiotics to treat drug-resistant infections and diseases.

Scientists zoom in on microbial messages at the molecular level to understand how the microbiome shapes health.